We strive to integrate chemistry and biology to address diverse biomedical problems. One of our interests is to develop therapeutics against therapy-resistant cancers. Cancer cells exploit different mechanisms to develop resistance against therapeutics. We are developing inhibitors and artificial degraders of the proteins/enzymes that contribute to the therapy-resistance of cancer cells. We are also developing novel strategies to deliver these therapeutics selectively into cancer cells. Another area of our interest is protein misfolding and aggregation that are at the forefront of several amyloid disorders. With a special emphasis on systemic amyloidoses, we are developing small molecules that inhibit aggregation of associated proteins as well as remove their toxic aggregates. We employ protein engineering, biochemistry, and chemical biology techniques to understand the mechanism of these diseases.
